Hormones of the Cardiovascular System

Endocrinology: Adult and Pediatric, Sixth Edition

Volumn 2, Issue , 2010, Pages 2036-2052

  Rademaker, Miriam T ^a   Espiner, Eric ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952817587     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5583-9.00111-8     Document Type: Chapter

References (154)

1. AJ de Bold, HB Borenstein, AT Veress, et al. (1981) A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28 89-94.
2. LR Potter, S Abbey-Hosch and DM Dickey (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endo Rev 27 47-72.
3. H Ruskoaho (1992) Atrial natriuretic peptide: Synthesis, release, and metabolism. Pharmacol Rev 44 479-602.
4. JC Chan, O Knudson, F Wu, et al. (2005) Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A 102 785-790.
5. TC Prickett, TG Yandle, MG Nicholls, et al. (2001) Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun 286 513-517.
6. DG Gardner, S Chen, DJ Glenn, et al. (2007) Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 49 419-426.
7. T Majalahti, M Suo-Palosaari, B Sarman, et al. (2007) Cardiac BNP gene activation by angiotensin II in vivo. Mol Cell Endocrinol 273 59-67.
8. A Weidemann, B Klanke, M Wagner, et al. (2008) Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem J 409 233-242.
9. T Horio, T Tokudome, T Maki, et al. (2003) Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 144 2279-2284.
10. TD Chrisman, S Schulz, LR Potter, et al. (1993) Seminal plasma factors that cause large elevations in cellular cyclic GMP are C-type natriuretic peptides. J Biol Chem 268 3698-3703.
11. MB Anand-Srivastava (2005) Natriuretic peptide receptor-C signaling and regulation. Peptides 26 1044-1059.
12. DM Dickey, DR Flora, PM Bryan, et al. (2007) Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 148 3518-3522.
13. P Moffatt, G Thomas, K Sellin, et al. (2007) Osteocrin is a specific ligand of the natriuretic peptide clearance receptor that modulates bone growth. J Biol Chem 282 36454-36462.
14. K Pankow, Y Wang, F Gembardt, et al. (2007) Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 101 875-882.
15. S Suga, K Nakao, H Itoh, et al. (1992) Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta, Possible existence of “vascular natriuretic peptide system.”. J Clin Invest 90 1145-1149.
16. MC Mendonca, SQ Doi, S Glerum, et al. (2006) Increase of C-type natriuretic peptide expression by serum and platelet-derived growth factor-BB in human aortic smooth muscle cells is dependent on protein kinase C activation. Endocrinology 147 4169-4178.
17. PR Kalra, JR Clague, AP Bolger, et al. (2003) Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 107 571-573.
18. CJ Charles, TCR Prickett, EA Espiner, et al. (2006) Regional sampling and the effects of experimental heart failure in sheep: differential responses in A, B and C-type natriuretic peptides. Peptides 27 62-68.
19. T Walther and H Stepan (2004) C-type natriuretic peptide in reproduction, pregnancy and fetal development. J Endocrinol 180 17-22.
20. RC Olney (2006) C-type natriuretic peptide in growth: a new paradigm. Growth Horm IGF Res 16 S6-S14.
21. AJ Houben, K van der Zander and PW de Leeuw (2005) Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol 19 411-419.
22. DM Heublein, BK Huntley, G Boerrigter, et al. (2007) Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 49 1114-1119.
23. K Sabrane, MN Kruse, L Fabritz, et al. (2005) Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 115 1666-1674.
24. A Luchner and H Schunkert (2004) Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system. Cardiovasc Res 63 443-449.
25. I Pagel-Langenickel, J Buttgereit, M Bader, et al. (2007) Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy. J Mol Med 85 797-810.
26. CJ Garland and KA Dora (2008) Evidence against C-type natriuretic peptide as an arterial “EDHF,”. Br J Pharmacol 153 4-5.
27. H Tsuneyoshi, T Nishina, T Nomoto, et al. (2004) Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair. Circulation 110 II174-II179.
28. AM Kapoun, F Liang, G O’Young, et al. (2004) B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94 453-461.
29. JY Qian, A Haruno, Y Asada, et al. (2002) Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ Res 91 1063-1069.
30. K Yamahara, H Itoh, TH Chun, et al. (2003) Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci U S A 100 3404-3409.
31. H Obata, B Yanagawa, K Tanaka, et al. (2007) CNP infusion attenuates cardiac dysfunction and inflammation in myocarditis. Biochem Biophys Res Commun 356 60-66.
32. LH Cao and XL Yang (2008) Natriuretic peptides and their receptors in the central nervous system. Prog Neurobiol 84 234-248.
33. JA Waschek (2004) Developmental actions of natriuretic peptides in the brain and skeleton. Cell Mol Life Sci 61 2332-2342.
34. H Schmidt, A Stonkute, R Juttner, et al. (2007) The receptor guanylyl cyclase Npr2 is essential for sensory axon bifurcation within the spinal cord. J Cell Biol 179 331-340.
35. A Yasoda, Y Komatsu, H Chusho, et al. (2004) Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nature Med 10 80-86.
36. TD Chrisman and DL Garbers (1999) Reciprocal antagonism coordinates C-type natriuretic peptide and mitogen-signaling pathways in fibroblasts. J Biol Chem 274 4293-4299.
37. P Krejci, B Masri, V Fontaine, et al. (2005) Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci 118 5089-5100.
38. AM Vollmar (2005) The role of atrial natriuretic peptide in the immune system. Peptides 26 1086-1094.
39. Y Wang, MC de Waard, A Sterner-Kock, et al. (2007) Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail 9 548-557.
40. MH Olsen, TW Hansen, MK Christensen, et al. (2005) N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 46 660-666.
41. PJ Hunt, EA Espiner, AM Richards, et al. (1995) Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. Am J Physiol 269 R1397-R1403.
42. AS McLean, SJ Huang, S Hyams, et al. (2007) Prognostic values of B-type natriuretic peptide in severe sepsis and septic shock. Crit Care Med 35 1019-1026.
43. PR Forfia, SP Watkins, JE Rame, et al. (2005) Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 45 1667-1671.
44. T Nakayama (2005) The genetic contribution of the natriuretic peptide system to cardiovascular diseases. Endocr J 52 11-21.
45. DM Hodgson-Zingman, ML Karst, LV Zingman, et al. (2008) Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 359 158-165.
46. M Davis, E Espiner, G Richards, et al. (1994) Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343 440-444.
47. LB Daniels and AS Maisel (2007) Natriuretic peptides. J Am Coll Cardiol 50 2357-2368.
48. E Braunwald (2008) Biomarkers in heart failure. N Engl J Med 358 2148-2159.
49. WH Tang, GS Francis, DA Morrow, et al. (2007) National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116 e99-e109.
50. K Park, H Itoh, K Yamahara, et al. (2008) Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. Endocrinology 149 483-491.
51. O Lisy, BK Huntley, DJ McCormick, et al. (2008) Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 52 60-68.
52. A Inoue, M Yanagisawa, S Kimura, et al. (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 86 2863-2867.
53. S Motte, K McEntee and R Naeije (2006) Endothelin receptor antagonists. Pharmacol Ther 110 386-414.
54. NS Kirkby, PW Hadoke, AJ Bagnall, et al. (2008) The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153 1105-1119.
55. FL Marasciulo, M Montagnani and MA Potenza (2006) Endothelin-1: the yin and yang on vascular function. Curr Med Chem 13 1655-1665.
56. WG Haynes and DJ Webb (1998) Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16 1081-1098.
57. N Dhaun, DM Pollock, J Goddard, et al. (2007) Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 28 573-579.
58. M Iglarz and M Clozel (2007) Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 50 621-628.
59. A Lerman, FL Hildebrand, LL Aarhus, et al. (1991) Endothelin has biological actions at pathophysiological concentrations. Circulation 83 1808-1814.
60. W Neuhofer and D Pittrow (2006) Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 36(Suppl 3), 78-88.
61. AB Strawbridge, JS Elmendorf and KJ Mather (2006) Interactions of endothelin and insulin: expanding parameters of insulin resistance. Curr Diabetes Rev 2 317-327.
62. MJ Grimshaw (2007) Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer 14 233-244.
63. G Hans, K Deseure and H Adriaensen (2008) Endothelin-1-induced pain and hyperalgesia: a review of pathophysiology, clinical manifestations and future therapeutic options. Neuropeptides 42 119-132.
64. Y Kurihara, H Kurihara, H Suzuki, et al. (1994) Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368 703-710.
65. M Schichiri, Y Hirata, K Ando, et al. (1990) Postural change and volume expansion affect plasma endothelin levels. JAMA 263 661.
66. MR Zamora, RF O’Brien, RB Rutherford, et al. (1990) Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 336 1144-1147.
67. K Yokokawa, H Tahara, M Kohno, et al. (1991) Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med 114 213-215.
68. S Ergul, DC Parish, D Puett, et al. (1996) Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 28 625-655.
69. PA Stevens and MJ Brown (1995) Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J Cardiovasc Pharmacol 26 9-12.
70. S Herrmann, K Schmidt-Petersen, J Pfeifer, et al. (2001) A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J 22 1948-1953.
71. A Vasku, L Spinarova, M Goldbergova, et al. (2002) The double heterozygote of two endothelin-1 gene polymorphisms (G8002A and -3A/-4A) is related to big endothelin levels in chronic heart failure. Exp Mol Pathol 73 230-233.
72. R Scacchi, G Gambina, E Broggio, et al. (2008) C-338A polymorphism of the endothelin-converting enzyme (ECE-1) gene and the susceptibility to sporadic late-onset Alzheimer's disease and coronary artery disease. Dis Markers 24 175-179.
73. M Kozak, LI Holla, L Krivan, et al. (2002) Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia. Med Sci Monit 8 BR164-BR167.
74. C Fonseca, E Renzoni, P Sestini, et al. (2006) Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum 54 3034-3042.
75. D Maixnerova, M Merta, J Reiterova, et al. (2007) The influence of three endothelin-1 polymorphisms on the progression of IgA nephropathy. Folia Biol (Praha) 53 27-32.
76. C Tzourio, M El Amrani, O Poirier, et al. (2001) Association between migraine and endothelin type A receptor (ETA-231 A/G) gene polymorphism. Neurology 56 1273-1277.
77. L Holla, A Vasku, V Znojil, et al. (1999) Association of 3 gene polymorphisms with atopic diseases. J Allergy Clin Immunol 103 702-708.
78. SH Kim, JY Kim, DM Kim, et al. (2006) Investigations on the association between normal tension glaucoma and single nucleotide polymorphisms of the endothelin-1 and endothelin receptor genes. Mol Vis 12 1016-1021.
79. M Inoue, T Kusafuka and A Okada (1998) Endothelin B receptor system and Hirschsprung disease. Nippon Rinsho 56 1876-1880.
80. H Gu, L Yang, N Tang, et al. (2008) Association of endothelin-converting enzyme-1b C-338A polymorphism with gastric cancer risk: A case-control study. Eur J Cancer 44 1253-1258.
81. V Vasku, JA Vasku, MP Goldbergova, et al. (2004) Association of variants in angiotensin-converting enzyme and endothelin-1 genes with phototherapy in cutaneous T-cell lymphoma. Acta Dermatovenerol Alp Panonica Adriat 13 111-116. 118
82. S Masson, R Latini, IS Anand, et al. (2006) Val-HeFT investigators, The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 12 375-380.
83. D Aronson and AJ Burger (2003) Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin. Pacing Clin Electrophysiol 26 703-710.
84. SQ Khan, O Dhillon, J Struck, et al. (2007) C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester acute myocardial infarction peptide (LAMP) Study. Am Heart J 154 736-742.
85. H Zhu and CH Shi (2007) Analysis of the diagnostic value of plasma endothelin for diabetic retinopathy using the receiver operating characteristic curve. Ophthalmic Res 39 289-293.
86. KJ Hartemink, AB Groeneveld, MC de Groot, et al. (2001) Alpha-atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock. Crit Care Med 29 80-87.
87. D Benzer, AD Aygun, A Godekmerdan, et al. (2006) Serum endothelin-1 and transforming growth factor-beta levels in the newborns with respiratory distress. Mediators Inflamm 2006 85432.
88. N Tekin, EC Dinleyici, MA Aksit, et al. (2007) Plasma and urinary endothelin-1 concentrations in asphyxiated newborns. Neuroendocrinol Lett 28 284-288.
89. Z Zietkowski, R Skiepko, MM Tomasiak, et al. (2008) Endothelin-1 in exhaled breath condensate of stable and unstable asthma patients. Respir Med 102 470-474.
90. GE Carpagnano, SA Kharitonov, AU Wells, et al. (2003) Increased vitronectin and endothelin-1 in the breath condensate of patients with fibrosing lung disease. Respiration 70 154-160.
91. P Schuetz, D Stolz, B Mueller, et al. (2008) Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect Dis 8 22.
92. R Grenda, E Wuhl, M Litwin, et al. (2007) ESCAPE Trial group, Urinary excretion of endothelin-1 (ET-1), transforming growth factor-beta1 (TGF- beta1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Nephrol Dial Transplant 22 3487-3494.
93. L Margarit, AN Griffiths, V Tsapanos, et al. (2007) Second trimester amniotic fluid endothelin-1 concentrations and subsequent development of intrauterine growth restriction. Eur J Obstet Gynecol Reprod Biol 134 192-195.
94. M Lalich, DG McNeel, G Wilding, et al. (2007) Endothelin receptor antagonists in cancer therapy. Cancer Invest 25 785-794.
95. M Settergren, J Pernow, K Brismar, et al. (2008) Endothelin-A receptor blockade increases nutritive skin capillary circulation in patients with type 2 diabetes and microangiopathy. J Vasc Res 45 295-302.
96. JR Teerlink (2002) Reversal of left ventricular remodeling: Role of the endothelin pathway. J Card Fail 8 S494-S499.
97. TM Kolettis, GG Baltogiannis, DG Tsalikakis, et al. (2008) Effects of dual endothelin receptor blockade on sympathetic activation and arrhythmogenesis during acute myocardial infarction in rats. Eur J Pharmacol 580 241-249.
98. P Cernacek, DJ Stewart, JC Monge, et al. (2003) The endothelin system and its role in acute myocardial infarction. Can J Physiol Pharmacol 81 598-606.
99. S Bien, A Riad, CA Ritter, et al. (2007) The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res 67 10428-10435.
100. M Ukai, H Yuyama, A Fujimori, et al. (2008) In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract. Eur J Pharmacol 580 394-400.
101. M Deja, T Busch, S Wolf, et al. (2004) Inhalation of the endothelin-A receptor antagonist LU-135252 at various doses in experimental acute lung injury. J Cardiovasc Pharmacol 44(Suppl 1), S151-S155.
102. N Sabaa, L de Franceschi, P Bonnin, et al. (2008) Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 118 1924-1933.
103. A Somell, E Weitzberg, A Suneson, et al. (2007) Effects of the dual endothelin receptor antagonist tezosentan and hypertonic saline/dextran on porcine endotoxin shock. Acta Physiol (Oxf) 190 291-302.
104. I Korzonek-Szlacheta and B Gwozdz (2007) Effects of endothelin-1 on prevention of microvascular endothelium injuries in hemorrhagic shock in rats. Pharmacol Rep 59 98-106.
105. YH Lai, HZ Wang, CP Lin, et al. (2008) Endothelin-1 enhances corneal fibronectin deposition and promotes corneal epithelial wound healing after photorefractive keratectomy in rabbits. Kaohsiung J Med Sci 24 254-261.
106. K Kitamura, K Kangawa, M Kawamoto, et al. (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192 553-560.
107. T Ishimitsu, H Ono, J Minami, et al. (2006) Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 111 909-927.
108. D Bell and BJ McDermott (2008) Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems. Br J Pharmacol 153 S247-S262.
109. DC Bunton, MC Petrie, C Hillier, et al. (2004) The clinical relevance of adrenomedullin: a promising profile? Pharmacol Ther 103 179-201.
110. J Kato, T Tsuruda, T Kita, et al. (2005) Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol 25 2480-2487.
111. T Nishikimi, T Horio, T Sasaki, et al. (1997) Cardiac production and secretion of adrenomedullin are increased in heart failure. Hypertension 30 1369-1375.
112. M Li, D Yee, TR Magnuson, et al. (2006) Reduced maternal expression of adrenomedullin disrupts fertility, placentation, and fetal growth in mice. J Clin Invest 116 2653-2662.
113. B Yanagawa and N Nagaya (2007) Adrenomedullin: molecular mechanisms and its role in cardiac disease. Amino Acids 32 157-164.
114. K Meeran, D O'Shea, PD Upton, et al. (1997) Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: A pharmacokinetic study. J Clin Endocrinol Metab 82 95-100.
115. H Kamoi, H Kanazawa, K Hirata, et al. (1995) Adrenomedullin inhibits the secretion of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, from rat alveolar macrophages. Biochem Biophys Res Commun 211 1031-1035.
116. M Nakamura, B Han, O Nunobiki, et al. (2006) Adrenomedullin: a tumor progression factor via angiogenic control. Curr Cancer Drug Targets 6 635-643. Review
117. J Cornish, D Naot and IR Reid (2003) Adrenomedullin: A regulator of bone formation. Regul Pept 112 79-86.
118. M Julian, M Cacho, MA Garcia, et al. (2005) A new target for the design of small molecule modulators with promising pharmacological activities. Eur J Med Chem 40 737-750.
119. B Temmesfeld-Wollbruck, AC Hocke, N Suttorp, et al. (2007) Adrenomedullin and endothelial barrier function. Thromb Haemost 98 944-951.
120. T Ishimitsu, T Nishikimi, H Matsuoka, et al. (1996) Behaviour of adrenomedullin during acute and chronic salt loading in normotensive and hypertensive subjects. Clin Sci 91 293-298.
121. J Kato, K Kitamura, T Uemura, et al. (2002) Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res Clin Exp 25 887-892.
122. AA Senna, M Zedan, GE el-Salam, et al. (2008) Study of plasma adrenomedullin level in normal pregnancy and preeclampsia. Medscape J Med 10 29.
123. K Ehlenz, B Koch, P Preuss, et al. (1997) High levels of circulating adrenomedullin in severe illness: correlation with C-reactive protein and evidence against the adrenal medulla as site of origin. Exp Clin Endocrinol Diabetes 105 156-162.
124. C Letizia, S Cerci, M Centanni, et al. (1998) Circulating levels of adrenomedullin in patients with Addison's disease before and after corticosteroid treatment. Clin Endocrinol 48 145-148.
125. B Cheung and R Leung (1997) Elevated plasma levels of human adrenomedullin in cardiovascular, respiratory, hepatic and renal disorders. Clin Sci 92 59-62.
126. BB Ceyhan, S Karakurt and N Hekim (2001) Plasma adrenomedullin levels in asthmatic patients. J Asthma 38 221-227.
127. H Yamamoto, S Teramoto, Y Yamaguchi, et al. (2007) Effect of nasal continuous positive airway pressure treatment on plasma adrenomedullin levels in patients with obstructive sleep apnea syndrome: roles of nocturnal hypoxia and oxidant stress. Hypertens Res Clin Exp 30 1065-1076.
128. SC Lim, NG Morgenthaler, T Subramaniam, et al. (2007) The relationship between adrenomedullin, metabolic factors, and vascular function in individuals with type 2 diabetes. Diabetes Care 30 1513-1519.
129. MT Garcia-Unzueta, VM Martinez-Taboada, JA Amado-Senaris, et al. (2006) Plasma adrenomedullin levels in patients with polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol 24 S6-S9.
130. K Ando and T Fujita (2003) Lessons from the adrenomedullin knockout mouse. Regul Pept 112 185-188.
131. SA Hamid and GF Baxter (2006) A critical cytoprotective role of endogenous adrenomedullin in acute myocardial infarction. J Mol Cell Cardiol 41 360-363.
132. S Iimuro, T Shindo, N Moriyama, et al. (2004) Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res 95 415-423.
133. K Caron, J Hagaman, T Nishikimi, et al. (2007) Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males. Proc Natl Acad Sci U S A 104 3420-3425.
134. Y Li, JA Staessen, LH Li, et al. (2006) Blood pressure and urinary sodium excretion in relation to the A-1984G adrenomedullin polymorphism in a Chinese population. Kidney Int 69 1153-1158.
135. K Kanozawa, T Shimosawa, R Nagasawa, et al. (2002) Mature form of adrenomedullin is a useful marker to evaluate blood volume in hemodialysis patients. Am J Kidney Dis 40 794-801.
136. K Shinomiya, K Ohmori, H Ohyama, et al. (2001) Association of plasma adrenomedullin with carotid atherosclerosis in chronic ischemic stroke. Peptides 22 1873-1880.
137. M Nakatsuka, T Habara, S Noguchi, et al. (2003) Increased plasma adrenomedullin in women with recurrent pregnancy loss. Obstet Gynecol 102 319-324.
138. D Gazzolo, E Marinoni, L Giovannini, et al. (2001) Circulating adrenomedullin is increased in preterm newborns developing intraventricular hemorrhage. Pediatr Res 50 544-547.
139. P Florio, R Abella, E Marinoni, et al. (2008) Adrenomedullin blood concentrations in infants subjected to cardiopulmonary bypass: correlation with monitoring parameters and prediction of poor neurological outcome. Clin Chem 54 202-206.
140. SQ Khan, RJ O’Brien, J Struck, et al. (2007) Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 49 1525-1532.
141. H Nishida, T Horio, Y Suzuki, et al. (2008) Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: comparison with C-reactive protein and adiponectin. Peptides 29 599-605.
142. A Gegenhuber, J Struck, B Dieplinger, et al. (2007) Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13 42-49.
143. S Ueda, K Nishio, N Minamino, et al. (1999) Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med 160 132-136.
144. M Christ-Crain, NG Morgenthaler, D Stolz, et al. (2006) Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care 10 R96.
145. EN Obineche, JY Pathan, S Fisher, et al. (2006) Natriuretic peptide and adrenomedullin levels in chronic renal failure and effects of peritoneal dialysis. Kidney Int 69 152-156.
146. HA Savas, H Herken, M Yurekli, et al. (2002) Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 45 57-61.
147. SS Zoroglu, H Herken, M Yurekli, et al. (2002) The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatr Res 36 309-315.
148. JG Lainchbury, MG Nicholls, EA Espiner, et al. (1999) Bioactivity and interactions of adrenomedullin and brain natriuretic peptide in patients with heart failure. Hypertension 34 70-75.
149. DO McGregor, RW Troughton, C Frampton, et al. (2001) Hypotensive and natriuretic actions of adrenomedullin in subjects with chronic renal impairment. Hypertension 37 1279-1284.
150. N Nagaya, S Kyotani, M Uematsu, et al. (2004) Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 109 351-356.
151. SO Iseri, Y Ersoy, N Gedik, et al. (2008) Protective role of adrenomedullin in burn-induced remote organ damage in the rat. Regul Pept 146 99-105.
152. B Yanagawa, M Kataoka, S Ohnishi, et al. (2007) Infusion of adrenomedullin improves acute myocarditis via attenuation of myocardial inflammation and edema. Cardiovasc Res 76 110-118.
153. T Miseki, H Kawakami, M Natsuizaka, et al. (2007) Suppression of tumor growth by intra-muscular transfer of naked DNA encoding adrenomedullin antagonist. Cancer Gene Ther 14 39-44.
154. E Dobrzynski, D Montanari, J Agata, et al. (2002) Adrenomedullin improves cardiac function and prevents renal damage in streptozotocin-induced diabetic rats. Am J Physiol 283 E1291-E1298.